Recombinant Anti-CEA x Anti-DR5 Bispecific Antibody (scIgG) (SCIGG-136)

Recombinant Anti-CEA x Anti-DR5 Bispecific Antibody (scIgG) is designed to be expressed as two chains, each chain has the same units with their parental IgG antibodies, anti-CEA and anti-DR5 IgGs. The two chains form heterodimer via Fc KIH technology. This BsAb can induce targeted apoptosis by activation of the death receptor. It is designed for the research of Breast cancer; Ovary cancer; Colon cancer; Lung cancer therapy.

Datasheet INQUIRY

Specifications

Targets

CEA & DR5

Type

Single chain IgGs

Species Reactivity

Human

Application

FuncS; Promising therapeutic agent

Related Disease

Breast cancer; Ovary cancer; Colon cancer; Lung cancer

Targets

Target 1

CEA

Gene ID

1048

UniProt ID

A0A024R0K5

Alternative Names

CEACAM5; carcinoembryonic antigen; carcinoembryonic antigen related cell adhesion molecule 5; CEA; CD66e; meconium antigen 100

Target 2

DR5

Gene ID

8795

UniProt ID

O14763

Alternative Names

DR5; Death Receptor 5; CD262; KILLER; TRICK2; TRICKB; ZTNFR9; TRAILR2; TRICK2A; TRICK2B; TRAIL-R2; KILLER/DR5; Tumor necrosis factor receptor superfamily member 10B; TNFRSF10B

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Anti-CEA x Anti-DR5 Bispecific Antibody (scIgG) (SCIGG-136). Click the button below to contact us or submit your feedback about this product.

Recombinant Anti-CEA x Anti-DR5 Bispecific Antibody (scIgG) (CAT#: SCIGG-136)

Specifications

Targets

Customer Reviews and Q&As